eISSN: 1897-4295
ISSN: 1734-9338
Advances in Interventional Cardiology/Postępy w Kardiologii Interwencyjnej
Current issue Archive Manuscripts accepted About the journal Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications
1/2024
vol. 20
 
Share:
Send email
Share:
abstract:
Original paper

Magnesium bioresorbable scaffold (Magmaris) versus polymer biodegradable ultrathin drug-eluting stent (Ultimaster) in acute coronary syndrome. Mid-term outcomes (2 years)

Adrian Włodarczak
1
,
Piotr Rola
2
,
Szymon Włodarczak
1
,
Marek Szudrowicz
1
,
Joanna Jaroszewska-Pozorska
1
,
Mateusz Barycki
2
,
Łukasz Furtan
2
,
Michalina Kędzierska
3
,
Adrian Doroszko
4
,
Maciej Lesiak
5

  1. Department of Cardiology, The Copper Health Centre (MCZ), Lubin, Poland
  2. Department of Cardiology, Provincial Specialized Hospital Legnica, Legnica, Poland
  3. Faculty of Medicine, Wroclaw Medical University, Wroclaw, Poland
  4. Department of Cardiology, Center for Heart Diseases, 4th Military Hospital, Faculty of Medicine, Wroclaw University of Science and Technology, Wroclaw, Poland
  5. 1st Department of Cardiology, University of Medical Sciences, Poznan, Poland
Adv Interv Cardiol 2024; 20, 1 (75): 67–75
DOI: https://doi.org/10.5114/aic.2024.136901
Online publish date: 2024/03/22
View full text Get citation
 
Introduction:
Acute coronary syndrome (ACS) is a well-known risk factor for adverse clinical outcomes in percutaneous coronary intervention (PCI). Therefore, evaluation of coronary stents in this challenging clinical scenario can provide unique information on device safety and efficacy. Bioresorbable scaffolds (BRS) were designed to overcome long-term complications related to permanent vessel caging with a permanent metallic drug-eluting stent (DES).

Aim:
We designed this study to evaluate the mid-term safety and efficiency of the Magmaris BRS in comparison to the leading new-generation ultrathin DES Ultimaster in the ACS population.

Material and methods:
We present a retrospective analysis of 2-year follow-up data. The primary outcomes consisted of death from cardiac causes, myocardial infarction, and in-stent thrombosis. The second main study endpoint was defined as target-lesion failure (TLF).

Results:
The study population consisted of two cohorts, the first of 193 patients treated with Magmaris implantation and the second of 169 patients treated with Ultimaster implantation. At the 2-year follow-up, there were no significant differences in both study cohorts in terms of primary outcome (5.1% vs. 11%; p = 0.051), and TLF (5.6% vs. 8%, p = 0.41).

Conclusions:
Treatment with a second-generation BRS (Magmaris) versus a novel second-generation DES (Ultimaster) in non-ST-elevation acute coronary syndrome (NSTE-ACS) was associated with similar rates of target lesion failure at 2-year follow-up.

keywords:

bioresorbable scaffold, Magmaris, magnesium, Ultimaster, acute coronary syndrome, polymer biodegradable, drug-eluting stent, mid-term
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2024 Termedia Sp. z o.o.
Developed by Bentus.